Bristol-Myers Squibb (BMS; NYSE: BMY) has released the final results from a Phase II trial evaluating the potential first-in-class LPA1 antagonist BMS-986278 in the treatment of progressive pulmonary fibrosis (PPF). The trial’s findings indicate that the twice-daily pill significantly reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 69% compared to a placebo, demonstrating its potential efficacy in managing this debilitating condition.
Efficacy and Tolerability of BMS-986278
The company reported that BMS-986278 not only showed a substantial reduction in the decline of lung function, as measured by ppFVC, but also exhibited a favorable tolerability profile. This suggests that the drug is well-tolerated and may offer a viable treatment option for patients suffering from PPF.
Implications for Pulmonary Fibrosis Treatment
The final results from the Phase II trial provide encouraging evidence for the potential of BMS-986278 in the treatment of progressive pulmonary fibrosis. As the drug moves through the clinical development pipeline, it may offer new hope for patients in need of effective therapies to slow the progression of this life-threatening disease.-Fineline Info & Tech
